Exchange: NYSE·Updated 11:31 AM EDT
News
all
press releases
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
Zacks
More News
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer
NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
Zacks
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
Zacks
Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio
MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.
Zacks
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
Zacks
ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?
ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.
Zacks
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.
Zacks
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
Zacks
CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.
Zacks

Advertisement|Remove ads.